Efficacy and safety of calf spleen extract injection combined with S-1 in the treatment of advanced primary squamous cell carcinoma of the stomach
CHEN Long1 WANG Lin4 HE Donglei2 LIANG Dong1 LIN Haifeng3 FENG Jun1 HUANG Ping4
1.Department of Oncology, the Third People′s Hospital of Hainan Province Nongken Sanya Hospital, Hainan Province, Sanya 572000, China;
2.Department of Gastrointestinal Cancer Surgery, the First Affiliated Hospital of Hainan Medical College, Hainan Province, Haikou 570100, China;
3.Department of Oncology, the Second Affiliated Hospital of Hainan Medical College, Hainan Province, Haikou 570100, China;
4.Department of Gastrointestinal Cancer Surgery, Hainan General Hospital, Hainan Province, Haikou 570100, China
Abstract：Objective To compare the efficacy and safety of calf spleen extract injection combined with S-1 in the treatment of advanced primary squamous cell carcinoma of the stomach. Methods A total of 31 advanced primary squamous cell carcinoma of the stomach patients with Karnofsky Performance Status (KPS) score≥60 scores and expected survival time≥3 months were enrolled from September 2011 to January 2017 in the Third People′s Hospital of Hainan Province and Hainan General Hospital. They were divided into the study group and the control group by random number table method, with 16 cases in the study group and 15 cases in the control group respectively. The patients in the study group received calf spleen extract injection combined with oral S-1 treatment. The control group received oral S-1 treatment. Each group was treated for three weeks. The efficacy and adverse events in the two groups were observed and compared post treatment for 3 months. Results The effective rates in the study group and the control group were 50.0% and 33.3% respectively, the disease control rates were 87.5% and 66.7% respectively, and the effective rate and disease control rate in the study group were both higher than those in the control group the differences were statistically significant(P ＜ 0.05). The median survival was 10.0 months in the study group and 7.0 months in the control group, the differences were statistically significant (P ＜ 0.05). The most common adverse events in the two groups were myelosuppression, diarrhea, nausea and vomiting, oral mucositis, allergy, renal impairment and so on, the incidence of adverse reactions in the two groups had no significant difference (P ＞ 0.05). Conclusion Efficacy and safety of calf spleen extract injection combined with S-1 in the treatment of advanced primary squamous cell carcinoma of the stomach are better than S-1， with less adverse reactions and it is worth clinical promotion.
陈珑1 王琳4 何冬雷2 梁冬1 林海锋3 冯军1 黄平4. 替吉奥联合小牛脾提取物注射液治疗中晚期胃鳞癌的效果和安全性[J]. 中国医药导报, 2018, 15(20): 124-128.
CHEN Long1 WANG Lin4 HE Donglei2 LIANG Dong1 LIN Haifeng3 FENG Jun1 HUANG Ping4. Efficacy and safety of calf spleen extract injection combined with S-1 in the treatment of advanced primary squamous cell carcinoma of the stomach. 中国医药导报, 2018, 15(20): 124-128.
[1] Callacondo D，Ganoza-Salas A，Anicama-Lima W，et al. Primary squamous cell carcinoma of the stomach with paraneoplastic leukocytosis：a case report and review of literature [J]. Hum Pathol，2009，40（10）：1494-1498.
[2] Schmidt C，Schmid A，Lüttges JE，et al. Primary squamous cell carcinoma of the stomach Report of a case and review of literature [J].Hepatogastroenterology，2001，48（40）：1033-1036.
[3] Parks RE. Squamous neoplasms of the stomach [J]. Am J Roentgenol Radium Ther Nucl Med，1967，101（2）：447-449.
[4] Wakabayashi H，Matsutani T，Fujita I，et al. A rare case of primary squamous cell carcinoma of the stomach and a review of the 56 cases reported in Japan [J]. J Gastric Cancer，2014，14（1）：58-62.
[5] Zhang Q，Zhao C. Primary squamous cell carcinoma of the stomach：A case report [J]. Ulus Cerrahi Derg，2015，32（3）：221-223.
[6] 孙宇萍，王季颖，吕梅君，等.小牛脾提取物注射液联合化疗治疗晚期非小细胞肺癌的临床疗效[J].中国癌症杂志，2008，18（6）：442-445.
[7] 李多，胡燕，李冬琼，等.小牛脾提取物注射液联合胸膜腔局部化疗治疗恶性胸腔积液的临床观察[J].中国现代医学杂志，2016，26（23）：107-110.
[8] 兰四友，张德芬，邓述恺，等.小牛脾提取物联合化疗治疗小细胞肺癌的临床疗效[J].中国老年学，2017，37（2）：401-403.
[9] 刘杰，吴格怡.小牛脾提取物注射液对肺癌患者免疫功能的影响[J].齐齐哈尔医学院学报，2015，36（11）：1638-1639.
[10] 王军伟，张静，刘晓英，等.小牛脾提取物对卵巢上皮性恶性肿瘤术后化疗患者的疗效及对MMP-2和CA125的影响[J].实用癌症杂志，2017，32（11）：1780-1783.
[11] 张素芳，孟昭琳，张玉芳.小牛脾提取物注射液联合化疗治疗晚期食管癌44例[J].肿瘤学杂志，2009，15（7）：638-640.
[12] 万一元，惠红霞，王晓炜，等.卡培他滨或替吉奥联合奥沙利铂方案治疗进展期胃癌的疗效及安全性[J].中华肿瘤杂志，2016，38（1）：28-34.
[13] 王传金.替吉奥治疗老年晚期胃肠道恶性肿瘤的临床疗效观察[J].中国实用医药，2017，12（28）：157-159.
[14] 王王玮，吴昌平，孙文辉，等.替吉奥和卡培他滨用于晚期结直肠癌维持治疗的疗效[J].江苏医药，2015，41（19）：2318-2319.
[15] 张金书，徐祥成，裴磊.替吉奥胶囊与5-氟尿嘧啶辅助治疗晚期直肠癌的疗效对比[J].中国普通外科杂志，2015，24（9）：1341-1344.
[16] 焦洋，宁洁，王芳，等.晚期乳腺癌替吉奥与卡培他滨治疗疗效及安全性对比研究[J].中华肿瘤防治杂志，2016， 23（7）：452-456.
[17] Boku N，Yamamoto S，Fukuda H，et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer：a randomized phase 3 study [J]. Lancet Oncol， 2009，10（11）：1063-1069.
[18] 李颖，姜达，吴圆圆，等.替吉奥和卡培他滨治疗进展期乳腺癌的多中心临床研究[J].中华肿瘤杂志，2017，39（8）：607-612.
2018, Vol. 15 
京公网安备 11010502046598号